Waters Corp

Waters Corp. gains “Outperform” upgrades and bullish RSI as its LC‑MS innovations, FDA clearance, and strategic biopharma partnership boost investor confidence.

Waters Corp’s stock hits new highs—boosted by a strong pipeline, 12% revenue growth, and an “Outperform” upgrade, positioning it ahead of peers in analytical tech.

Waters Corporation has reported positive financial results for the second quarter, exceeding street estimates and raising its full-year 2025 guidance.

Waters Corporation’s stock price has demonstrated stability, with a premium valuation reflecting investors’ confidence in its future growth prospects.

Waters Corp has announced a strategic partnership with Becton Dickinson, merging a Becton Dickinson unit with Waters’ Biosciences & Diagnostic Solutions division to create a leading bioscience and diagnostics company.

Waters Corp has announced a $17.5 billion partnership with Becton Dickinson, set to create a medical testing giant with a projected $40 billion addressable market.

Waters Corporation has introduced BioResolve Protein A Affinity Columns, a game-changing innovation that accelerates the development of lifesaving therapies by streamlining upstream bioprocessing and improving sensitivity.